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ABSTRACT
Acute lymphoblastic leukemia (ALL) in infants is an aggressive malignancy with 
a poor clinical outcome, and is characterized by translocations of the Mixed Lineage 
Leukemia (MLL) gene. Previously, we identified RAS mutations in 14-24% of infant 
ALL patients, and showed that the presence of a RAS mutation decreased the survival 
chances even further. We hypothesized that targeting the RAS signaling pathway 
could be a therapeutic strategy for RAS-mutant infant ALL patients. Here we show 
that the MEK inhibitors Trametinib, Selumetinib and MEK162 severely impair primary 
RAS-mutant MLL-rearranged infant ALL cells in vitro. While all RAS-mutant samples 
were sensitive to MEK inhibitors, we found both sensitive and resistant samples 
among RAS-wildtype cases. We confirmed enhanced RAS pathway signaling in RAS-
mutant samples, but found no apparent downstream over-activation in the wildtype 
samples. However, we did confirm that MEK inhibitors reduced p-ERK levels, and 
induced apoptosis in the RAS-mutant MLL-rearranged ALL cells. Finally, we show 
that MEK inhibition synergistically enhances prednisolone sensitivity, both in RAS-
mutant and RAS-wildtype cells. In conclusion, MEK inhibition represents a promising 
therapeutic strategy for MLL-rearranged ALL patients harboring RAS mutations, while 
patients without RAS mutations may benefit through prednisolone sensitization.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) in infants 
(<1 year of age) represents an aggressive malignancy, 
associated with high relapse rates and a poor clinical 
outcome [1]. The majority (~80%) of these patients 
carry a leukemia-specific chromosomal translocations 
involving the Mixed Lineage Leukemia (MLL) gene [1]. 
MLL-rearranged infant ALL patients fare significantly 
worse than infant ALL patients who do not carry MLL 
translocations, with event-free survival rates of 30-40% 
vs. ~80%, respectively [2]. Recently, we demonstrated 
that 24% of the infant ALL patients carrying MLL 
translocation t(4;11), the most frequently observed 
translocation of MLL among these patients, also carry a 
RAS mutation. Mutations in NRAS were found in 11% 
and KRAS mutations in 13% of cases [3]. Moreover, we 
showed that the presence of a RAS mutation in MLL-
rearranged patients represented an independent predictive 
factor for an even worse clinical outcome in this high-
risk group. Nearly all RAS-mutant t(4;11)+ infant ALL 
patients relapsed within the first year from diagnosis, 
while still on treatment, and all died within 4 years from 
diagnosis [3].
Despite this strong association with an exceedingly 
poor prognosis, a recent study by Emerenciano et 
al. suggested that RAS mutations in MLL-rearranged 
infant ALL may not act as driver mutations and are not 
required for disease progression, but rather act only at 
disease onset [4]. Yet, our previous data clearly showed 
that RAS-mutant MLL-rearranged infant ALL patients 
are at extremely high risk of therapy failure and early 
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death. Moreover, RAS pathway inhibition, including 
MEK inhibition, was previously shown to effectively 
inhibit RAS-mutant MLL-rearranged AML in vitro [5, 
6]. Therefore, we decided to investigate the potential of 
RAS pathway inhibition and found that RAS-mutant MLL-
rearranged ALL cells are remarkably sensitive to MEK 
inhibitors.
RESULTS
RAS-mutant MLL-rearranged ALL cells are 
sensitive to MEK inhibition
Since the previously identified RAS aberrations 
are all activating mutations (at residues G12, G13 or 
Q61), we wondered whether small molecule inhibitors 
targeting RAS pathway components could suppress RAS-
mutant leukemic cells [3, 7]. Therefore, 7 RAS pathway 
inhibitors, already approved for therapeutical use or under 
clinical investigation for other malignancies with RAS 
pathway mutations, were selected as therapeutic strategies 
for the RAS-mutant infant ALL patients. Using 4-day MTS 
cell viability assays we tested the in vitro anti-leukemic 
potential of Salirasib (RAS localization inhibitor), 
Vemurafenib (BRAF inhibitor), Sorafenib (pan-kinase 
inhibitor), Trametinib, Selumetinib and MEK162 (MEK 
inhibitors) and Temsirolimus (mTOR inhibitor) against 
RAS-mutant MLL-rearranged ALL cell line KOPN8, and 
the RAS-wildtype MLL-rearranged cell lines SEM and 
RS4;11. Interestingly, the RAS-mutant cell line KOPN8 
was more sensitive to the MEK inhibitors MEK162, 
Selumetinib and Trametinib (Figure 1). Temsirolimus 
and Sorafenib potently reduced cell viability of both 
RAS-mutant and RAS-wildtype cell lines. Additionally, 
Salirasib and Vemurafenib did not substantially reduce 
cell viability, even at high concentrations (>10μM). To 
confirm the efficacy of these inhibitors, we performed 
4-day MTT cell viability assays on primary diagnostic 
RAS-mutant (n=6) and RAS-wildtype (n=14) t(4;11)+ 
infant ALL samples. Interestingly, compared to RAS-
wildtype t(4;11)+ ALL cases, the RAS-mutant t(4;11)+ 
infant ALL cases were significantly more sensitive to 
all MEK inhibitors (Figure 2A) with median IC50 values 
of <0.1 μM for MEK162 and Selumetinib and <0.01 
μM for Trametinib (Figure 2B). Additionally, all other 
tested inhibitors (Salirasib, Temsirolimus, Sorafenib 
and Vemurafenib) reached only IC50 values of >10μM 
(Supplementary Figure 1).
Also, we included one matched pair of diagnostic/
relapse t(4;11)+ samples. For this particular patient, 
no RAS mutation was present at diagnosis, but a RAS 
mutation could be identified at relapse. Indeed, the RAS-
mutant relapse sample of this patient was more sensitive 
to all three MEK inhibitors tested than the RAS-wildtype 
diagnostic sample (Figure 2B).
Enhanced RAS activation in t(4;11)+ infant ALL 
cells carrying RAS mutations
The MEK inhibitors MEK162, Selumetinib and 
Trametinib significantly reduce viability of RAS-mutant 
MLL-rearranged ALL cells. Notably, a subset of the 
RAS-wildtype primary t(4;11)+ infant ALL samples also 
responded favorably to the MEK inhibitors (Figure 2B). 
We wondered whether other biomarkers, besides RAS 
mutation status, could predict MEK inhibitor sensitivity 
in MLL-rearranged ALL. Wildtype RAS proteins are under 
regulation of upstream signaling events, often involving 
tyrosine kinase receptors, while mutant RAS proteins 
are less dependent on upstream activation due to reduced 
GTPase activity, rendering a surplus of activated GTP-
bound RAS. Therefore, we determined the RAS protein 
levels and RAS activity in our primary t(4;11)+ infant 
ALL cells. No significant difference in RAS protein 
levels was observed between the RAS-mutant and RAS-
wildtype t(4;11)+ infant ALL samples using Western blot 
analysis (Figure 3A). Next, we investigated the level of 
active (GTP-bound) RAS in these samples by precipitation 
with RAF-1 RAS interaction peptide, followed by 
immunoblotting. As expected, the RAS-mutant t(4;11)+ 
infant ALL samples showed significant (p=0.013) higher 
levels of RAS activation as compared to RAS-wildtype 
samples (Figure 3B). No differences in RAS activation 
were observed between RAS-wildtype samples that were 
sensitive or resistant to MEK inhibition.
Subsequently, we determined phosphorylation levels 
of MEK (p-MEK) and ERK (p-ERK) by immunoblotting 
(Supplementary Figure 2A and 2B, respectively). 
Quantification of the blots indicated a significantly higher 
level of p-MEK in our RAS-mutant samples, compared to 
RAS-wildtype samples (p=0.0312, Figure 3C), although 
there was no difference in p-MEK levels between the 
MEK inhibitor resistant and sensitive RAS-wildtype 
subgroups. Still, we did find a higher p-MEK level in the 
mutated relapse sample compared to its matched wildtype 
diagnosis sample. Additionally, no differences in p-ERK 
levels were found between RAS-wildtype and RAS-mutant 
samples (Figure 3D), nor between RAS-wildtype cells that 
were sensitive or resistant to MEK inhibition.
In MLL-rearranged AML, MEK inhibitor 
resistance can occur through activation of tyrosine kinase 
receptor (TKR) signaling (i.e. involving VEGFR-2) [5]. 
Furthermore, we previously found MLL-rearranged ALL 
is characterized by high expression of Fms-like tyrosine 
kinase 3 (FLT3) [8]. Therefore, we interrogated available 
gene expression profiles of primary samples for possible 
differences in TKR expression levels between the MEK 
inhibitor sensitive and resistant subgroups (Supplementary 
Figure 3). Interestingly, apart from FLT3, expression of 
TKRs is relatively low in the different patient samples. 
Surprisingly, FGFR-1 expression is significantly lower in 
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MEK inhibitor resistant RAS-wildtype samples (p=0.02), 
while there are no significant differences in expression of 
FLT3, VEGFR (1-3), FGFR (2-4), EGFR and ERBB (2-4), 
PDGFR (A-B) or Lck and Src.
MEK inhibition results in reduced ERK 
phosphorylation
Next, we exposed MLL-rearranged ALL cell lines 
SEM and KOPN8 to the MEK inhibitors (Selumetinib, 
MEK162 and Trametinib) and determined p-ERK and 
p-MEK levels by immunoblotting (Figure 4). Interestingly, 
p-ERK levels were drastically reduced in both SEM 
and KOPN8, already after 6 hours of exposure, and this 
effect was sustained for at least 48 hours, regardless of 
the inhibitor used (Figure 4A). Furthermore, prolonged 
exposure (24 and 48 hours) to the MEK inhibitors 
Selumetinib and MEK162 resulted in an increase of 
p-MEK in SEM and KOPN8 (Figure 4B). Additionally, we 
determined phosphorylation of ERKs downstream effector 
ELK-1, but ELK-1 activation was not influenced by MEK 
inhibition (Supplementary Figure 4A).
Since SEM cells responded modestly to MEK 
inhibition but did show a significant loss of p-ERK levels, 
Figure 1: MEK inhibitors specifically impede RAS-mutant MLL-rearranged ALL cell line KOPN8. Cell viability of MLL-
rearranged cell lines exposed to MEK162, Selumetinib, Trametinib, Temsirolimus, Sorafenib, Salirasib and Vemurafenib. All cell lines 
respond to Sorafenib and Temsirolimus, while RAS-mutant KOPN8 (solid line) is more sensitive for MEK162, Selumetinib and Trametinib 
than RAS-wildtype SEM (large dashed line) or RS4;11 (small dashed line). Data are represented as mean +/- sem. n≥3.
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we investigated whether these cells could circumvent 
loss of ERK activation by upregulating RAS-mediated 
PI3K-Akt-mTOR signaling. Therefore, the downstream 
phosphorylation of Akt (Ser437) and p70S6K (Thr389) 
was assessed by immunoblotting. However, no differences 
in Akt and p70S6K phosphorylation were observed in 
response to MEK inhibitor exposure (Supplementary 
Figure 4B and 4C).
MEK inhibitors induce apoptosis
Subsequently, we investigated the phenotypic effects 
of the MEK inhibitors on SEM and KOPN8 through 
analysis of early and late apoptosis markers (Annexin-V 
and 7-AAD, respectively), using flow-cytometry. 
Interestingly, both RAS-wildtype SEM and RAS-mutant 
KOPN8 undergo early apoptosis, after treatment with 
MEK inhibitor (Figure 5A and 5B, respectively). 
However, while late apoptosis is barely observed for SEM 
(Figure 5C), late apoptosis in MEK inhibitor exposed 
KOPN8 cells is enhanced substantially, especially 
after prolonged exposure (Figure 5D), suggesting the 
response to MEK inhibition is characterized by increased 
apoptosis. Furthermore, MEK inhibitor exposure induced 
protein levels of pro-apoptotic BIM, most evidently 
for KOPN8, while p53 levels remained unaffected 
(Supplementary Figure 5). Additionally, we investigated 
cell cycle progression under influence of MEK inhibition. 
Interestingly, no considerable differences in SEM or 
KOPN8 cell cycle progression were observed after 96 
hours exposure to MEK162, Selumetinib or Trametinib 
(Figure 5E and 5F, respectively), nor after exposure for 
24, 48 and 72 hours (Supplementary Figure 6A-6B, 6C-6D 
and 6E-6F, respectively).
MEK inhibition enhances prednisolone 
sensitivity
In our previous study, we found that MLL-rearranged 
infant ALL patient samples harboring RAS mutations 
are more resistant to prednisolone [3]. Therefore, we 
examined whether inhibition of MEK could enhance 
prednisolone sensitivity of RAS-mutant cells. As shown in 
Figure 6A, prednisolone alone decreased cell viability of 
SEM cells to only ~50%. Interestingly, while Trametinib 
by itself induced only minor cell viability decrease in 
SEM cells (Figure 6B), the combination of Trametinib 
and prednisolone greatly enhanced the efficacy of 
prednisolone, especially at higher concentrations (Figure 
6A). The combination of prednisolone and Trametinib 
also strongly decreased cell viability in KOPN8 more 
potently than either drug alone; low concentrations of 
Trametinib nearly eradicated all KOPN8 cells that did not 
respond to prednisolone treatment (Figure 6C). A similar 
sensitizing effect was observed when exposing SEM and 
KOPN8 to MEK162 or Selumetinib in combination with 
prednisolone (Supplementary Figure 7A-7D and 7F-7I, 
respectively). Since Trametinib alone already effectively 
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Figure 2: Primary RAS-mutant MLL-rearranged ALL cells are sensitive to MEK inhibitors. A. Patient derived t(4;11)+ 
infant ALL cells exposed to MEK inhibitors indicate RAS-mutant samples (solid line, n=6) are more sensitive compared to RAS-wildtype 
samples (dashed line, n=14). Data are represented as median +/- sd. *0.01<p<0.05; **0.001<p<0.01; ***p<0.001. B. The IC50 (concentration 
needed to inhibit 50% of the leukemic cell viability) of the individual t(4;11)+ infant ALL patient samples shown in A. Median IC50 
values, represented by horizontal bars, confirm strong sensitivity of RAS-mutant patient samples compared to the majority of RAS-wildtype 
samples. Open circles indicate matched diagnosis (wildtype) and relapse (mutant) samples. The tick lines indicate separation between MEK 
inhibitor sensitive and resistant patient samples (IC50<1μM and IC50>1μM, respectively).
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decreases viability of KOPN8 cells (Figure 6D), we 
quantified the combinatorial effect of MEK inhibitors and 
prednisolone using the synergy factor (FSyn) calculation, 
as previously described [9, 10]. The plot in Figure 6E 
shows the fractional effect (i.e. the relative decrease of 
cell viability) induced by the combination of Trametinib 
with prednisolone, and the corresponding Synergy Factor. 
Interestingly, in both SEM and KOPN8 cells we observed 
FSyn values < 0.5, indicating strong synergy between 
Trametinib and prednisolone. Also combining MEK162 
or Selumetinib with prednisolone resulted in moderate 
to strong synergistic effects (Supplementary Figure 
7E and 7J, respectively). Additionally, we investigated 
whether this enhanced effect was related to differential 
expression of the glucocorticoid receptor (GR), the target 
of prednisolone. However, MEK inhibitor exposure did 
not alter GR protein levels in either SEM or KOPN8 cells 
(Supplementary Figure 7K).
DISCUSSION
MLL-rearranged ALL in infants is a high-risk 
hematologic malignancy, characterized by a high 
incidence of relapse and high mortality rate [11]. Recently, 
we showed that 14-24% of these patients carry a RAS 
mutation, as an independent predictor of extremely poor 
Figure 3: RAS-mutant t(4;11)-positive ALL cells have enhanced downstream activation. A. RAS protein level, relative 
to β-actin, determined by western blotting in t(4;11)+ infant ALL samples, subdivided according to RAS mutation status (WT or MUT) 
and MEK inhibitor sensitivity (Res or Sens). No differences in median protein level (horizontal bars) are observed between the different 
subgroups. B. Relative RAS activation is enhanced in RAS-mutant t(4;11)+ patient samples, though no difference is observed between the 
MEK inhibitor resistant and sensitive RAS-wildtype subgroups. C. Ratio p-MEK/total MEK in RAS-mutant (MUT) and RAS-wildtype (WT) 
t(4;11)-rearranged infant ALL samples shows increased MEK activation in RAS-mutant samples, while the MEK inhibitor resistant and 
sensitive RAS-wildtype samples have comparable MEK activation. D. Ratio p-ERK/total ERK in RAS-mutant and RAS-wildtype t(4;11)-
rearranged infant ALL samples shows no significant differences in ERK activation between subgroups. Open circles indicate matched 
diagnosis (wildtype) and relapse (mutant) samples. Horizontal bars present group medians. Open circles indicate matched diagnosis 
(wildtype) and relapse (mutant) samples. *p<0.05.
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outcome [3]. In the present study, we demonstrate that the 
MEK inhibitors Trametinib, Selumetinib and MEK162 
display strong anti-leukemic effects against RAS-mutant 
MLL-rearranged ALL cells. Considering the dismal 
prognosis for infants suffering from MLL-rearranged 
ALL with additional RAS mutations, our data supports 
application of these inhibitors in the treatment of this 
patient group. Recently, Irving et al. already showed that 
Selumetinib effectively inhibits leukemia progression in 
an in vivo model of RAS-mutant BCP-ALL, and Burgess 
et al. found Trametinib to prolong the survival of mice 
transplanted with NRASG12D AML cells [12, 13]. Moreover, 
Trametinib has recently been approved for the treatment 
of adult BRAF-mutated melanoma, while different clinical 
trials with Selumetinib and MEK162 show promising 
results in adult patients with RAS/RAF mutation positive 
melanoma and non-small-cell lung cancer [14–18]. Even 
though most clinical trials focused on solid tumors in 
adult patients, pediatric clinical trials are underway for 
neurofibromas and gliomas, and could expedite clinical 
application of these MEK inhibitors in MLL-rearranged 
infant ALL.
Interestingly, while all RAS-mutant MLL-rearranged 
ALL patient samples are susceptible to MEK inhibition, 
patients without RAS mutations also might benefit from 
MEK inhibitor treatment, since a subgroup of RAS-
wildtype patient samples appears sensitive to MEK 
inhibition. While in our previous study, we identified RAS 
mutations and found no BRAF aberrations, mutations of 
other upstream regulators, i.e. tyrosine kinase receptors, 
can occur in other malignancies [3]. Andersson et al. 
recently showed that additional somatic mutations in 
MLL-rearranged infant ALL, like (sub-)clonal RAS/
PI3K pathway aberrations, occur in up to 50% of the 
cases, supporting our previous observation that RAS 
mutations in MLL-rearranged infant ALL frequently 
Figure 4: MEK inhibition results in reduced ERK phosphorylation. A. Western blot analysis of SEM and KOPN8 (upper and 
lower panels, respectively) exposed to 500 nM of MEK inhibitor or vehicle control (DMSO) for 6, 24 and 48 hours. Both cell lines almost 
completely lose ERK phosphorylation (p-ERK), while total ERK (t-ERK) levels remain unaffected. B. Analysis of MEK phosphorylation 
(p-MEK) suggests exposure to MEK162 and Selumetinib results in enhanced MEK phosphorylation in both cell lines, whereas total MEK 
(t-MEK) levels remain constant.
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occur at a sub-clonal level [3, 19]. These findings do not 
support the hypothesis that other (upstream) mutations 
are driving RAS-MEK-ERK signaling, but also do not 
explain observed extensive MEK inhibitor sensitivity of 
all (subclonal) RAS-mutant and specified RAS-wildtype 
patient samples. While we found enhanced RAS and MEK 
activation in RAS-mutant samples, these biomarkers could 
not differentiate MEK inhibitor sensitive and resistant 
RAS-wildtype samples. Interestingly, Kampen et al. 
recently proposed a MEK inhibitor escape mechanism in 
MLL-rearranged AML, which was mediated by VEGFR-2 
and PI3K-signaling, and we wondered whether this could 
Figure 5: MEK inhibitors induce apoptosis. A. and B. Early apoptosis (percentage AnnexinV single positive of total) of SEM and 
KOPN8 cells (respectively) after exposure to DMSO vehicle (white bars) or 500 nM MEK162, Selumetinib or Trametinib (light grey, dark 
grey and black bars, respectively), indicates MEK inhibition slightly induces early apoptosis. Data are represented as mean +/- sem. n=3. C. 
and D. Late apoptosis (percentage AnnexinV and 7-AAD double positive cells of total) of SEM and KOPN8 (respectively) show that while 
SEM cells have no induction of late apoptosis in response to MEK inhibition, compared to the DMSO controls, KOPN8 clearly undergoes 
apoptosis, especially after prolonged exposure (>48 hours). Data are represented as mean +/- sem. n=3. E. and F. Cell cycle analysis of 
SEM and KOPN8 (respectively) after 96 hours exposure to vehicle (DMSO) or 500 nM MEK162, Selumetinib or Trametinib indicates 
MEK inhibition does not impinge on the cell cycle progression. Stacked bar graph indicates percentage of cells in G0/G1 (black), S (grey) 
and G2/M (white) cell cycle stages. Data are represented as mean +/- sem. n=3.
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play a role in the MEK inhibitor resistance of our wildtype 
patient cells [5]. However, we observed no difference 
in downstream PI3K-signalling (i.e. Akt or p70S6K 
phosphorylation) in response to MEK inhibitor exposure. 
Additionally, we discovered no significant tyrosine kinase 
receptor expression differences in MLL-rearranged infant 
ALL patient samples that could explain the MEK inhibitor 
response of RAS-wildtype samples. Surprisingly, FGFR-1 
expression was lower in MEK inhibitor resistant samples, 
but it is unclear how this would explain MEK inhibitor 
resistance. Alternatively, Minjgee et al. report that RAS-
mutant transfected cells can induce downstream RAS 
signaling in a paracrine manner, through excretion of 
cytokines [20]. Interestingly, Nakanishi et al. previously 
demonstrated that MLL-fusion proteins can induce ERK 
phosphorylation through regulating EphA7 receptor 
tyrosine kinase expression, but this was not accompanied 
by increased RAF or MEK phosphorylation [21]. Still, 
Figure 6: MEK inhibition enhances prednisolone sensitivity. A. Dose-response curves of the SEM cell line exposed to prednisolone 
alone (black curve) or in combination with 0.04 μM, 0.2 μM, 1 μM or 5 μM Trametinib (red, blue, green and grey curves, respectively). 
Low concentrations of Trametinib particularly sensitize cells that escape high concentrations of prednisolone. Data are represented as mean 
+/- sem. n=3. B. Response of SEM to the single Trametinib concentrations used in A. n=3. C. Dose-response curves of KOPN8 treated 
with prednisolone (black curve), or in combination with the aforementioned Trametinib concentrations (shown in red, blue, green and 
grey, respectively). KOPN8 cells are also sensitized towards prednisolone by co-exposure with low concentrations of Trametinib. Data 
are represented as mean +/- sem. n=3 D. KOPN8 exposed to single Trametinib concentrations. Data are represented as mean +/- sem. n=3. 
E. Combined exposure to prednisolone and Trametinib (merged data from 3 separate experiments) was quantified using FSyn calculations 
(FSyn<1 indicates synergy) and plotted against fractional effect (i.e. inhibition of cell viability). In SEM (red) moderate to strong synergy was 
observed, while all combinations of Trametinib and prednisolone result in strong to very strong synergy in KOPN8 (blue).
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their data shows that leukemic cells carrying the t(4;11) 
translocation are sensitive to small molecule inhibitors of 
ERK phosphorylation. These findings indicate alternative 
regulatory mechanisms for ERK signaling in MLL-
rearranged leukemia could explain the MEK inhibitor 
sensitivity we observe in RAS-wildtype cells.
Loss of ERK phosphorylation in response 
to MEK162, Selumetinib or Trametinib exposure 
confirmed the effect of MEK inhibition. Interestingly, 
prolonged exposure of cells to MEK162 or Selumetinib 
resulted in increased MEK phosphorylation. Previously, 
Hatzivassiliou et al. showed that the aromatic fluorine of 
allosteric MEK inhibitor GDC-0973 interacts with MEK 
residue S212 [22]. Their data indicate this interaction 
results in exposure of the phosphorylation sites S218/
S222, which are then susceptible to RAF mediated 
phosphorylation. Since MEK162 and Selumetinib both 
have this aromatic fluorine, the mechanism of interaction 
with MEK is probably similar to GDC-0973. Hence, 
although MEK activation in presence of GDC-0973, 
MEK162 or Selumetinib can still occur, the transduction 
of the signal by MEK-mediated phosphorylation of ERK 
is no longer possible, as we show in Figure 4.
Recently, we found the presence of RAS mutations 
in MLL-rearranged infant ALL cells correlated with 
prednisolone resistance, an obstacle in the treatment of 
infant ALL [2, 3]. Remarkably, our present data shows 
that MEK inhibition strongly enhances the sensitivity 
of both RAS-wildtype and RAS-mutant MLL-rearranged 
ALL cells to prednisolone, also further exemplifying the 
possible value of MEK inhibitors for RAS-mutant, as well 
as RAS-wildtype, MLL-rearranged infant ALL patients. 
The prednisolone-sensitizing effect of MEK inhibitors 
proposes a possible role for RAS-MEK-ERK signaling in 
the response to glucocorticoids. Recent work by Jones et 
al. shows that MEK plays a key role in drug resistance 
in relapsed pediatric ALL, and that MEK inhibition can 
sensitize ALL relapse samples to chemotherapeutics, 
including methylprednisolone [23]. Moreover, Ariës 
et al. found Trametinib could restore prednisolone 
sensitivity in RAS-mutant BCP-ALL patient samples, 
whereas Rambal et al. showed that MEK activation 
reduces dexamethasone sensitivity, and the MEK inhibitor 
PD183452 enhanced dexamethasone responses in ALL 
cells in a BIM-dependent manner [24, 25]. Activated 
ERK can phosphorylate BIM, targeting it for proteasomal 
degradation, and thereby diminishing apoptosis induced by 
dexamethasone [26]. Moreover, we established that, while 
glucocorticoid receptor expression remains constant, MEK 
inhibition upregulates pro-apoptotic BIM, which implies 
that inhibiting MEK, resulting in abrogation of ERK 
phosphorylation, may result in prolonged maintenance of 
pro-apoptotic BIM activity upon prednisolone exposure, 
leading to enhanced prednisolone sensitivity. This is 
further supported by our previous study showing that in 
MLL-rearranged ALL, prednisolone sensitization mediated 
by pan-BCL-2 family inhibitors was largely driven by the 
up-regulation of pro-apoptotic BID and BIM [27].
In summary, our data shows that RAS-mutant 
MLL-rearranged infant ALL patients may benefit from 
therapeutic strategies administering small-molecule MEK 
inhibitors. Furthermore, since MEK inhibition sensitizes 
MLL-rearranged ALL cells to prednisolone regardless of 
the RAS mutations status, RAS-wildtype MLL-rearranged 
infant ALL patients may also benefit from MEK inhibitor 
treatment through enhanced sensitivity to prednisolone.
MATERIALS AND METHODS
Patient samples and cell lines
Bone marrow and peripheral blood samples from 
untreated infant ALL patients were collected at the Sophia 
Children’s Hospital (Rotterdam, The Netherlands) as part 
of the international collaborative INTERFANT treatment 
protocol [2]. Approval for these studies was obtained from 
the Erasmus MC Institutional Review Board. Informed 
consent was obtained according to the Declaration of 
Helsinki. All samples were processed within 24 hours 
after sampling as described before, with optional removal 
of contaminating non-leukemic cells by immunomagnetic 
beads, to ensure leukemic blast content for all samples was 
>90% [8]. The t(4;11)-rearranged ALL cell line SEM and 
t(11;19)-rearranged ALL cell line KOPN8 were purchased 
from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany), while the 
t(4;11)-rearranged ALL cell line RS4;11 was purchased 
from The Global Biosource Center (ATCC, Middlesex, 
UK). All cell lines were cultured in suspension in RPMI-
1640 with GlutaMAX (Invitrogen Life Technologies, 
Waltham, MA, USA) supplemented with 10% Fetal Calf 
Serum, 100 IU/mL penicillin, 100 IU/mL streptomycin 
and 0.125 μg/mL amphotericin B (Invitrogen Life 
Technologies) at 37°C under 5% CO2 atmosphere.
In vitro cytotoxicity assay and small molecule 
inhibitors
The in vitro cytotoxicity of MEK162, Selumetinib 
and Trametinib (MedChem Express, Stockholm, Sweden) 
was tested by MTS and MTT assays. All inhibitors were 
weighed, dissolved in dimethyl sulfoxide (DMSO) and 
stored at -20°C until use. Cytotoxicity assay dilutions 
were prepared in cell culture medium, keeping final 
DMSO concentration <0.5%. Final concentrations of 
the small molecule inhibitors ranged from 50 μM to 
0.15 nM, indicated in the respective figures. The in vitro 
sensitivity of cell lines was assessed by using 4-day MTS 
conversion assays, as described previously [28]. In vitro 
cytotoxicity of patient cells was assessed by using a 4-day 
MTT conversion assay, as described before [8]. Data were 
normalized to vehicle (DMSO) controls.
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Western blot analysis
Protein extracts (25 μg) were electrophoretically 
resolved on pre-cast SDS-polyacrylamide gels (anyKD, 
TGX, Bio-Rad, Veenendaal, The Netherlands) and 
transferred to nitrocellulose membranes. Membranes 
were blocked with 5% bovine serum albumin and 
subsequently probed with antibodies directed against 
total or phosphorylated ERK, MEK, ELK-1, Akt, 
or p70S6K (Cell Signaling, Danvers, MA, USA). 
Membranes were counterstained with IRDye® 680/800 
conjugated secondary antibodies (Li/COR, Leusden, 
The Netherlands) and were scanned by an Odyssey 
imaging system (Li/COR). Membranes were re-probed 
with mouse monoclonal anti-β-actin antibodies (Sigma-
Aldrich, St. Louis, MO, USA) as loading control. 
Fluorescence was quantified using the Odyssey 3.0 
application software.
RAS activation
RAS activation was analyzed using the RAS 
Activation Assay Kit (17-218, Merck-Millipore, 
Amsterdam, The Netherlands). Briefly, 1x107 cells 
were isolated and lysed with Mg2+ Lysis Buffer (MLB), 
and stored at -80°C until use. GST-fused RAF-1 RBD 
bead slurry was added to the lysate and incubated for 
1 hour at 4°C while agitating. Beads were isolated by 
centrifugation and washed with MLB, and precipitated 
protein was denatured with Laemmli buffer at 95°C 
before immunoblotting. As a positive control, total cell 
lysate was included in the immunoblotting procedure. 
The provided RAS antibody (05-516, Merck-Millipore) 
was used, and GST (Cell Signaling) and β-actin (Sigma-
Aldrich) antibodies were used as loading controls for 
the beads and total protein, respectively. Fluorescence 
was quantified using the Odyssey 3.0 application 
software.
Annexin-V/7-AAD apoptosis and cell cycle 
assays
For assessment of early and late apoptosis, the PE 
Annexin-V Apoptosis Detection Kit (BD Pharmingen, 
Breda, The Netherlands) was used according to the 
manufacturer’s protocol. Briefly, drug-exposed cells were 
isolated, washed with PBS and re-suspended in binding 
buffer. Cells were stained with PE Annexin V and/or 
7-AAD for 15 minutes, and sorted using fluorescence 
activated cell sorting (FACS). Cell cycle progression was 
assessed by permeabilization of isolated cells through 
hypotonic lysis. Subsequently, RNAse treatment was 
performed, and DNA was stained using Propidium Iodide, 
after which FACS determined DNA content. Data was 
analyzed using FlowJo software (FlowJo, Ashland, OR, 
USA).
Gene expression data
Recently published gene expression data 
(Affymetrix HU133plus2.0) for part of the t(4;11)+ patient 
samples was available (i.e. for 6 of 9 MEK inhibitor 
resistant RAS-wildtype samples, 4 of 5 sensitive RAS-
wildtype samples and 3 of 6 RAS-mutant samples) [29]. 
This data is available in GEO database19 (accession 
number GSE19475) and was acquired as previously 
described [29]. Tyrosine kinase receptor expression was 
derived from this dataset, using the following probe sets: 
206674_at (FLT3), 204406_at (VEGFR-1), 203934_at 
(VEGFR-2), 234379_at (VEGFR-3), 210973_s_at 
(FGFR-1), 208225_at (FGFR-2), 204380_s_at (FGFR-3), 
204579_at (FGFR-4), 211551_at (EGFR), 210930_s_at 
(ERBB2), 226213_at (ERBB3), 214053_at (ERBB4), 
205463_s_at (PDGFR-A), 217112_at (PDGFR-B), 
204891_s_at (Lck) and 213324_at (Src).
Statistical analysis
Statistical analyses were performed with SPSS 
Statistics version 17.0 (SPSS Inc. Chicago, IL, USA). All 
tests were two-tailed and p-values < 0.05 were considered 
significant. The effect of combining drugs (i.e. synergy, 
additivity or antagonism) was assessed using Berenbaums 
criteria, as previously described [9, 10]. Briefly, we 
calculated the Synergy Factor (FSyn) with the formula FSyn 
= ([Drug Xin combination with Y]/[Drug X]) + ([Drug Yin combination 
with X] / [Drug Y]) for a particular fractional effect. If the 
drug combination results in FSyn < 1, this is considered 
synergy.
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